Drug intelligence / Profile preview

GSK6792538

Development stage: Unknown
Lead developer: GSK
Modality: Small Molecules
Administration: Oral

Overview

GSK6792538 is an investigational small molecule inhibitor of the **Transient Receptor Potential Canonical 5 (TRPC5)** channel. Developed by **GSK** (through its subsidiary **SB Pharmco Puerto Rico**), the drug is currently in Phase 1 clinical trials for the treatment of **glomerular nephropathies**, including focal segmental glomerulosclerosis (FSGS) and IgA nephropathy. TRPC5 is a non-selective cation channel that plays a critical role in podocyte health; its overactivation leads to calcium influx, cytoskeletal damage, and protein leakage into the urine. By selectively blocking TRPC5, GSK6792538 aims to preserve podocyte function and provide a targeted therapeutic approach for patients with proteinuric kidney diseases.

Other names: GSK-6792538GSK6792538GSK 6792538

Targets

TRPC5 (Transient receptor potential Canonical-5)

Beyond the preview

Go deeper on GSK6792538.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK6792538.

Explore the full profile